Bass and Spangenberg double down on IPR strategy
Hedge fund manager Kyle Bass and IP Nav’s Erich Spangenberg have filed a second inter partes review petition against a patent owned by Acorda Therapeutics, as part of a strategy BIO said had “opened a new door to abuse of the US patent system”
Bass, who runs Texas-based Hayman Capital, announced in January that he would take on some of the world’s biggest drug producers by challenging their patents through inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB).
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.